

AMENDMENTS TO THE CLAIMS

A complete listing of all claims is presented below with insertions underlined (e.g., insertion), and deletions struckthrough or in double brackets (e.g., ~~deletion~~ or ~~[[deletion]]~~):

1.-13. (Cancelled)

14. (Currently Amended) A prosthesis for placement at an opening from a main body lumen to a branch body lumen, the prosthesis comprising:

a radially expansible support, the support configured to be deployed in at least a portion of the branch body lumen, the support adapted to provide a first radial force to support a body lumen;

at least two elongate, flexible fronds each having a first end, a second end and an axially extending undulating elongate portion having a plurality of crests and troughs between the first and second ends ~~length in between,~~ at least a portion of the elongate portion comprising a plurality of spaced apart filaments having crests and troughs extending in-phase, the fronds extending from an end of the support and configured to be positioned across the Os and into the main body lumen; ~~and~~

at least one circumferential link comprising an undulating pattern including a plurality of crests and troughs, the circumferential link being connected at crests thereof to the second ends of the fronds, the circumferential link spaced axially apart from the support by the fronds and adapted to provide a second radial force that is less than the first radial force; and

a plurality of elongate side wall openings in between adjacent fronds sized and configured to receive a stent deployment device therethrough;

the elongate, flexible fronds, the support and the circumferential link defining a unitary body as deployed, ~~having~~ the elongate side wall openings in between adjacent fronds for facilitating crossing of a main vessel stent therethrough when the support is positioned in the branch body lumen and the circumferential link is positioned in the main body lumen.

15. **(Previously Presented)** The prosthesis as in Claim 14, wherein the circumferential link comprises an undulating pattern having at least three apexes.

16. **(Previously Presented)** The prosthesis as in Claim 14, comprising three fronds.

17. **(Previously Presented)** The prosthesis as in Claim 14, wherein at least one frond comprises a helical configuration.

18. **(Original)** The prosthesis as in Claim 17, comprising a plurality of helical fronds.

19. **(Previously Presented)** The prosthesis as in Claim 14, wherein at least a portion of the fronds comprises a lubricous coating.

20. **(Previously Presented)** The prosthesis as in Claim 14, wherein the fronds, have an axial length of at least about 8 mm.

21. **(Original)** The prosthesis as in Claim 14, wherein the circumferential link is radiopaque.

22. **(Previously Presented)** The prosthesis as in Claim 21, wherein the circumferential link has a greater radiopacity than the fronds.

23. **(Original)** The prosthesis as in Claim 14, comprising an endothelial cell ingrowth surface.

24. **(Original)** The prosthesis as in Claim 14, comprising a non thrombogenic surface.

25.-29. **(Cancelled)**

30.-35. **(Cancelled)**

36. **(Previously Presented)** The prosthesis as in Claim 14, wherein at least one frond comprises a plurality of parallel, undulating filaments.

37. **(Previously Presented)** The prosthesis as in Claim 36, wherein at least a portion of the radially expandible support comprises a drug coating, and at least a portion of the fronds and the circumferential link are without a drug coating.

38. **(Previously Presented)** The prosthesis as in Claim 37, wherein the drug coating is configured to produce at least one of a controlled drug release rate, a constant drug release rate, bi-modal drug release rate or a controlled concentration of drug proximate a target vessel wall.

39. **(Previously Presented)** The prosthesis as in Claim 37, wherein the drug is one of an anti-cell proliferative, anti cell migration, anti-neo plastic, and anti inflammatory drug.

40. **(Previously Presented)** The prosthesis as in Claim 37, wherein the drug is configured to reduce restenosis.

41. **(Previously Presented)** The prosthesis as in Claim 37, wherein the drug coating includes a first coating and a second coating.

42. **(Previously Presented)** The prosthesis as in Claim 41, wherein the first coating is configured to produce a first drug release rate and the second coating is configured to produce a second drug release rate.

43. **(Previously Presented)** The prosthesis as in Claim 14, wherein the circumferential link comprises a single transverse filament.

44. **(Previously Presented)** The prosthesis as in Claim 14, further comprising a transition section between the support and the fronds.

45.-46. **(Cancelled)**

47. **(Previously Presented)** The prosthesis of Claim 14, wherein the prosthesis includes a drug incorporated into a polymer matrix.

48. **(Cancelled)**

Appl. No. : 10/584,968
NP Filed : June 30, 2006

49. **(Previously Presented)** The prosthesis of Claim 47, wherein the polymer matrix includes a base layer and a top layer, the drug being incorporated into at least one of the top layer and the base layer.

50. **(Previously Presented)** The prosthesis of Claim 14, wherein the prosthesis includes one or more reservoirs configured to be loaded with a drug.

51. **(Previously Presented)** The prosthesis of Claim 50, wherein the prosthesis includes one or more drugs in the one or more reservoirs.